Genomics ADvISER

Genomics ADvISER is a digital decision aid for use in the delivery of genomic counseling. It is intended as a supplement to genomic counseling with a counselor. Genomics ADvISER guides users through a ten-minute video of basic genomic sequencing concepts and five categories of secondary findings followed by brief interactive questionnaires about values, knowledge, and decision-making needs. Please contact the authors of the study to use this tool.

CSER Phase 1: Personalized Medicine Based on Molecular Profiling of Pediatric and Young Adult Patients with Cancer Study Protocol

The Personalized Medicine Based on Molecular Profiling of Patients with Cancer implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4. Genes Queried; 5. Genetic Information Nondiscrimination Act.

CSER Phase 1: Personalized Oncology Through High-throughput Sequencing:
MI-ONCOSEQ Study Protocol

The Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) (formerly known as “Personalized Medicine Based on Molecular Profiling of Patients with Cancer”) study implements a mechanism for patients who have advanced or refractory cancer to undergo tumor sequencing, sequence analysis, and return of clinically significant sequence results to patients, their families and the clinicians. This document is the revised study protocol. It contains 5 appendices: 1. Study Calendar; 2. Sample Molecular Report; 3. Adverse Event Reporting Form; 4.

CSER Phase 1: Baylor Advancing Sequencing into Childhood Cancer Care (BASIC3) Germline Sequencing Form

This form is for physicians to record demographic and clinical information about a patient to facilitate laboratory interpretation of whole exome sequencing results. It also records family history of cancer and physician choice about receipt of carrier status information for autosomal recessive conditions.

CSER Phase 1: NCGENES "What can I learn from whole genome sequencing" Brochure

The brochure, developed by North Carolina Genomic Evaluation by Next-generation Exome Sequencing (NCGENES), includes information about whole exome sequencing (WES), the three types of incidental information revealed by WES (medically actionable, not medically actionable, and no known medical value), and how NCGENES will allocate participants into groups to study two return of results decision interventions.

Subscribe to Adults